Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?
新診斷的2型糖尿病:以體重減輕或血糖控制為主要治療目標?為何要選擇,當你可以兼顧兩者?
Drugs 2023-04-26
The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia.
長期使用葡萄糖樣肽-1受體激動劑(GLP-1RA)對沙特阿拉伯吉達的KAUH糖尿病患者HbA1c和脂質檔案的可能影響:一項回顧性研究。
Diseases 2023-03-30
Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
Exenatide每日兩次施用對第2型糖尿病患者體重指數降低的療效。
Int J Clin Pract 2023-05-24
Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.
糖尿病患者體重減輕的系統性回顧:葡萄糖樣肽-1受體激動劑的作用。
Cureus 2023-07-18
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.
GLP-1 受體激動劑對血糖控制程度和體重減輕幅度與動脈粥樣硬化心血管疾病風險之關聯:糖尿病心血管結果試驗的系統性回顧和荟萃分析。
Cardiovasc Drugs Ther 2024-01-12
Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
新型糖尿病藥物對心血管和腎臟結果治療效果的潛在中介因子:一項荟萃回歸分析。
J Am Heart Assoc 2024-04-14
EXPRESS: Glucagon-Like Peptide-1 Receptor Agonist Therapy Effects on Glycemic Control and Weight in a Primary Care Clinic Population.
EXPRESS: Glucagon-Like Peptide-1 受體激動劑療法對初級保健診所人群的血糖控制和體重影響。
J Investig Med 2024-07-30
Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
使用重複測量變異數分析的真實世界研究:GLP-1 受體激動劑在超重或肥胖型 2 型糖尿病中的應用。
Medicine (Baltimore) 2024-08-09
Importance of weight reduction in type 2 diabetes for the prevention of CVD outcomes: A systematic review of CVOTs.
2型糖尿病減重對心血管疾病結果預防的重要性:心血管臨床試驗的系統性回顧。
Diabetes Res Clin Pract 2024-08-15
Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.
iGlarLixi(Insulin Glargine 100 U/ml 和 Lixisenatide)在2型糖尿病(T2D)患者中根據基線 HbA1c 和 BMI 的實際效果。
Diabetes Ther 2024-09-14